Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Marc P BonacaElliott Marshall AntmanJonathan W CunninghamStephen D WiviottSabina A MurphyJonathan L HalperinJeffrey I WeitzMichael A GrossoHans J LanzEugene BraunwaldRobert P GiuglianoChristian T RuffPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Patients with AF and PAD are at heightened risk of MACEs and CV death vs. those without PAD. The efficacy and safety of edoxaban 60/30 mg vs. warfarin in AF are consistent regardless of PAD; however, edoxaban 30/15 mg is inferior for stroke prevention in AF patients with PAD. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT00781391.
Keyphrases